DreaMed Diabetes AI LTD. (“DreaMed” or the “Company“), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMed’s Advisor Pro – a digital diabetes management platform in one of the top 10 metropolitan U.S. children’s hospital1.
Advisor Pro by DreaMed Diabetes is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and therapy management tools. The solution was deployed at the hospital together with existing diabetes management protocols so patients can receive a personalized, precise, and effective diabetes treatment.
In the United States alone, 34.2 million people—just over 1 in 10—have diabetes. When it comes to youth diabetes, according to American Diabetes Association, about 210,000 Americans under age 20 are estimated to have been diagnosed with diabetes.
Advisor Pro is the first decision support system to receive FDA clearances for Type 1 and Type 2 diabetes treatments – for pediatrics and adults. The solution leverages AI to optimize insulin administration and assist healthcare providers in caring for diabetes patients who use insulin pumps or injections and monitor their glucose.
“I am thrilled to see DreaMed being used by providers and patients so soon after the recent FDA clearance,” says Eran Atlas, Founder, and CEO of DreaMed Diabetes. “Our first FDA clearance, which was for our Type 1 insulin pump solution, led to partnerships with leading diabetes treatment centers including Yale-New Haven Health, Texas Children’s Hospital, and the University of Florida.”
“Our fourth FDA clearance for our Type 1 & Type 2 solution on insulin injections opened the door to deeper collaborations with top-tier children’s hospitals to improve their diabetes management program for a much larger portion their paitent pannel. Our goal is to help people of all ages manage their diabetes optimally and achieve sustainable health improvement. I’m truly excited that a growing number of healthcare practitioners and their patients can benefit from our solution.”